Adherence to Antiretroviral Therapy in Turkey: Results from the ACTHIV-IST Study Group.

Maintaining optimal adherence to antiretroviral therapy (ART) is essential for optimizing the management of HIV infection. The aim of this study is to explore ART adherence rates in Turkey. Included in this study were a total of 263 HIV-infected patients followed up by the ACTHIV-IST (ACTion against HIV in Istanbul) Study Group affiliated with four tertiary hospitals. The study population included patients 18 years of age or older who were on ART for over 12 months. Adherence was assessed by the medication possession ratio (MPR) calculated for each patient using data (a list of all drugs dispensed within the previous year for that patient) obtained from pharmacy medication records. In addition, patients completed a self-report questionnaire addressing missed doses and the AIDS Clinical Trials Group (ACTG) adherence questionnaire. The study was reviewed and approved by the Ethics Committee of Cerrahpasa Medical Faculty. Patient ages ranged from 19 to 71 years. Two hundred and thirty-one patients were male (88%). Two hundred and twenty-four patients (85%) had optimal adherence (MPR ≥95%). During the course of ART, 236 patients (90%) reported no missed doses in the past 4 days of their treatment, whereas 206 patients (78%) reported no missed doses in the past month. Simply forgetting was the most common reason for nonadherence. MPR was associated with virologic rebound. Major factors affecting adherence were being female, taking antituberculosis drugs, having an opportunistic infection, being able to take all or most of the medication as directed, and being aware of the need to take medication exactly as instructed to prevent the development of drug resistance. Adherence to ART measured by MPR and self-report surveys is relatively high in Turkey when compared with other countries, which probably led to high ART success rates.

[1]  F. Wabwire-mangen,et al.  Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and Zambia , 2016, PloS one.

[2]  A. Çağatay,et al.  HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. , 2016, AIDS research and human retroviruses.

[3]  A. Gunduz,et al.  Severe manifestation of psoriasis in a HIV infected patient: a case report - , 2015 .

[4]  R. Ozaras,et al.  Epidemiological profile of naive HIV-1/AIDS patients in Istanbul: the largest case series from Turkey. , 2014, Current HIV research.

[5]  A. Westfall,et al.  Medication Possession Ratio Predicts Antiretroviral Regimens Persistence in Peru , 2013, PloS one.

[6]  V. Sychareun,et al.  Adherence to Antiretroviral Therapy (ART) among People Living With HIV (PLHIV): a cross-sectional survey to measure in Lao PDR , 2013, BMC Public Health.

[7]  B. Tran,et al.  Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study , 2013, Global health action.

[8]  N. Terrin,et al.  Medication Possession Ratio Associated with Short-Term Virologic Response in Individuals Initiating Antiretroviral Therapy in Namibia , 2013, PloS one.

[9]  A. Gadkari,et al.  The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis , 2012, AIDS care.

[10]  P. Simkhada,et al.  Factors Influencing Adherence to Antiretroviral Treatment in Nepal: A Mixed-Methods Study , 2012, PloS one.

[11]  S. Lewin,et al.  Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Lizheng Shi,et al.  Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis , 2010, Health and quality of life outcomes.

[13]  L. Chen,et al.  Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. , 2010, The Journal of antimicrobial chemotherapy.

[14]  K. Peltzer,et al.  Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa , 2010, BMC public health.

[15]  A. Phillips,et al.  Use of a prescription‐based measure of antiretroviral therapy adherence to predict viral rebound in HIV‐infected individuals with viral suppression , 2010, HIV medicine.

[16]  B. Yip,et al.  The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.

[17]  B. Chi,et al.  Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia , 2009, International journal of epidemiology.

[18]  R. Hogg,et al.  Differential impact of adherence on long-term treatment response among naive HIV-infected individuals , 2008, AIDS.

[19]  J. Miro,et al.  Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. , 2008, AIDS research and human retroviruses.

[20]  B. Chi,et al.  Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[21]  H. Nagaraja,et al.  Optimizing Measurement of Self-Reported Adherence With the ACTG Adherence Questionnaire: A Cross-Protocol Analysis , 2007, Journal of acquired immune deficiency syndromes.

[22]  M. Chesney,et al.  The Elusive Gold Standard: Future Perspectives for HIV Adherence Assessment and Intervention , 2006, Journal of acquired immune deficiency syndromes.

[23]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[24]  Peter W. Dillingham,et al.  Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death , 2004, International journal of STD & AIDS.

[25]  J. Bartlett Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance , 2004 .

[26]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[27]  A. Wu,et al.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.